Skip to main content

Table 4 Efficacy measures between two treatments from GI Discomfort Questionnaire

From: Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

Parameter Visit Placebo Active P value
Bloating Baseline 5.31 ± 0.82 5.88 ± 0.93 0.1372
Final Visit 5.93 ± 0.21 3.42 ± 0.31 0.0037*
Vomiting Baseline 4.88 ± 0.93 4.02 ± 0.55 0.1126
Final Visit 4.42 ± 0.36 2.13 ± 0.19 0.0013*
Diarrhea Baseline 5.79 ± 0.95 5.70 ± 0.76 0.1684
Final Visit 5.93 ± 0.54 3.25 ± 0.42 0.0026*
Stool frequency Baseline 5.41 ± 0.68 5.67 ± 0.58 0.1485
Final Visit 5.75 ± 0.11 3.11 ± 0.27 0.0031*
Abdominal pain Baseline 5.64 ± 0.77 5.71 ± 0.11 0.1539
Final Visit 5.93 ± 0.21 1.82 ± 0.49 0.0001*
  1. Values expressed as mean ± S.E
  2. *Statistically significant